- Kite's study reveals that Yescarta® is safe and effective for outpatient care in relapsed/refractory large B-cell lymphoma patients.
- Outpatient administration shows cost-effective advantages and could ease the burden on hospitals.
- Similar safety and efficacy outcomes were observed between outpatient and inpatient settings over a median follow-up of 12 months.
Santa Monica, Calif. — Kite, a Gilead Company (GILD, Financial), has unveiled encouraging real-world data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, supporting the use of Yescarta® (axicabtagene ciloleucel) for outpatient treatment in patients with relapsed/refractory large B-cell lymphoma. The study found comparable safety and effectiveness between patients treated in outpatient and inpatient settings.
Conducted using data from the Center for International Blood and Marrow Transplant Research registry, the study assessed 238 patients from 75 treatment centers, equally divided between outpatient and inpatient settings. The analysis spanned patients treated between July 2021 and November 2023. Results showed no significant differences in cytokine release syndrome or neurologic events between the groups, confirming that outpatient care can be as viable as traditional inpatient treatment.
With a median follow-up of 12 months, the results demonstrated that one-fourth of outpatient recipients did not require hospital admission within 30 days post-treatment. Furthermore, half of the outpatient patients avoided hospital admission within just 3 days, underscoring potential benefits like lessening the burden on healthcare systems.
"These findings suggest that outpatient therapy with Yescarta could potentially increase the accessibility of treatment while maintaining patient safety and healthcare quality," said Dominique Tonelli, M.D., Kite's Vice President and Global Head of Medical Affairs. The real-world evidence provides a basis for expanding access to one-time curative treatments with Yescarta, enhancing patient and family experiences while optimizing healthcare system efficiencies.
Yescarta continues to be a leading therapy for large B-cell lymphoma, offering new hope to the approximately 18,000 individuals diagnosed with the disease annually in the United States. As Kite explores broader application settings, the focus remains on delivering innovative treatments that balance efficacy, safety, and system-wide benefits.
